The following is a summary of the Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Coherus BioSciences reported a net product revenue of $76.7 million in Q1 2024, up 137% year over year.

• Revenue from UDENYCA was up by 63% compared to Q1 2023 and 18% from the last quarter to $42.7 million.

• The newly launched product, LOQTORZI generated $2 million in revenue.

• The company successfully reduced its structured term loan debt by 85% over a recent three-month period.

• Coherus reported a net income of $102.9 million in Q1 2024, compared to a net loss of $75.7 million during the same period in 2023.

• Cost of goods sold during Q1 2024 was $34.6 million, representing an 8% decrease from Q4 2023.

• R&D expenditures fell by $5.7 million even as SG&A costs increased by 15%.

• As of March 31, 2023, the company held cash and cash equivalents and investments in marketable securities of $259.8 million.

Business Progress:

• The business received FDA approval for the therapeutics LOQTORZ and UDENYCA, both of which are now on the market.

• The UDENYCA franchise has grown with the new UDENYCA on-body injector, expanding into more of the pegfilgrastin market.

• The company has broad development strategies for its immuno-oncology portfolio with internally developed assets, promising partnership opportunities, and external research collaborations.

• Coherus BioSciences has advanced its R&D pipeline, with clinical developments for products such as Casdozo and CHS-114.

• The company is expecting FDA feedback on the IND for CHS-1000 in the second quarter of 2024.

• Coherus BioSciences expects its key growth drivers in 2024 to be the UDENYCA on-body variant and is focusing on its newly launched products, LOQTORZI and UDENYCA's auto-injector. The company plans to achieve cash flow positivity by 2024.

More details: Coherus BioSciences IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.